We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01582880
First Posted: April 23, 2012
Last Update Posted: September 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Joseph B. Ciolino, MD, Massachusetts Eye and Ear Infirmary
  Purpose
The purpose of the pilot study is to test the efficacy and safety of riboflavin/Ultraviolet A (UVA) cross-linked human donor corneas as carriers for the Boston Keratoprosthesis (Boston KPro) in patients with higher risk for corneal melting (keratolysis).

Condition Intervention Phase
Chemical Injuries Unspecified Complication of Corneal Transplant Autoimmune Diseases Ocular Cicatricial Pemphigoid Stevens Johnson Syndrome Lupus Erythematosus, Systemic Rheumatoid Arthritis Other Autoimmune Diseases Drug: Riboflavin Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis

Resource links provided by NLM:


Further study details as provided by Joseph B. Ciolino, MD, Massachusetts Eye and Ear Infirmary:

Primary Outcome Measures:
  • Changes in Corneal Thickness at 1 Millimeter [ Time Frame: measured at week 4, 6, 26, 32, 52 ]
    The average carrier graft thickness over the first year of postoperative follow-up. The corneal thickness was measured at each visit using AS-OCT imaging 1 mm away from the KPro stem at 3, 6, 9, and 12 o'clock. The individual corneal thickness measurements (3, 6, 9, and 12 o'clock) where then averaged. The average corneal thickness measurements for week 4, 6, 26, 32 and 52 are reported below.

  • Changes in Corneal Thickness at 2 Millimeter [ Time Frame: measured at week 4, 6, 26, 32, 52 ]
    The average carrier graft thickness over the first year of postoperative follow-up. The corneal thickness was measured at each visit using AS-OCT imaging 2 mm away from the KPro stem at 3, 6, 9, and 12 o'clock. The individual corneal thickness measurements (3, 6, 9, and 12 o'clock) where then averaged. The average corneal thickness measurements for week 4, 6, 26, 32 and 52 are reported below.


Secondary Outcome Measures:
  • Number of Occurrences of Vitritis (Sterile or Infectious) Ulcers [ Time Frame: post op week 52 ]
    Number of occurrence of vitritis (sterile or infectious) ulcers. Incidences of ulcers were collected by way of slit lamp photography from time of surgery to final visit.

  • Ocular Safety [ Time Frame: measured at day 1, and week 1, 4, 8, 12, 16, 24, 36, 52 ]
    Incidence and severity of ocular adverse events during the study (ophthalmic examination, adverse events spontaneously reported)

  • Systemic Safety [ Time Frame: measured at day 1, and week 1, 4, 8, 12, 16, 24, 36, 52 ]
    Incidence and severity of systemic adverse events during the study (clinical laboratory, adverse events spontaneously reported).


Enrollment: 1
Study Start Date: March 2012
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Riboflavin Cross-linked donor cornea
the donor cornea used as a carrier for the Boston Keratoprosthesis will undergo crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
Drug: Riboflavin
Used to treat donor cornea before implantation
Other Name: Riboflavin (vitamin B2) 0.1% solution

Detailed Description:
The corneal cross-linking technique has been shown to strengthen the cornea and resist degradation by the body's own enzymes. The use of highly-resistant donor corneas is meant to eliminate the serious post-operative complication of corneal melting (keratolysis) that repeatedly occurs in Boston KPro patients with severe ocular burns, autoimmune and cicatrizing diseases.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ability to provide written informed consent and comply with study assessments for the full duration of the study.
  2. Age > 18 years.
  3. A negative urine pregnancy test.
  4. Candidate for a Boston Keratoprosthesis/Corneal transplant.
  5. Generally good stable overall health.
  6. Patients with an eye at risk for a cornea sterile ulcer which includes:

    • Chemical injuries.
    • Autoimmune diseases (ocular cicatricial pemphigoid, Stevens Johnson Syndrome, systemic lupus erythematosus, rheumatoid arthritis, or other autoimmune diseases).
    • History of previous sterile corneal ulceration requiring a cornea transplant.

Exclusion Criteria:

  1. Age < 18 years.
  2. Inability to provide written informed consent and comply with study assessments for the full duration of the study.
  3. Pregnant or lactating women.
  4. No or minimal tear production.
  5. Ocular or periocular malignancy.
  6. Inability to wear a contact lens due to lid abnormalities or shortened fornix.
  7. Signs of current infection, including fever and current treatment with antibiotics.
  8. Participation in another simultaneous medical investigation or trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01582880


Locations
United States, Massachusetts
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Joseph B. Ciolino, MD
Investigators
Principal Investigator: Joseph Ciolino, MD Massachusetts Eye and Ear Infirmary
  More Information

Responsible Party: Joseph B. Ciolino, MD, Principal Investigator, Massachusetts Eye and Ear Infirmary
ClinicalTrials.gov Identifier: NCT01582880     History of Changes
Other Study ID Numbers: 10-03-020
First Submitted: April 10, 2012
First Posted: April 23, 2012
Results First Submitted: March 21, 2017
Results First Posted: July 24, 2017
Last Update Posted: September 18, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Joseph B. Ciolino, MD, Massachusetts Eye and Ear Infirmary:
Keratoprosthesis
sterile cornea ulcer

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Lupus Erythematosus, Systemic
Pemphigoid, Bullous
Stevens-Johnson Syndrome
Pemphigoid, Benign Mucous Membrane
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Immune System Diseases
Skin Diseases, Vesiculobullous
Skin Diseases
Stomatitis
Mouth Diseases
Stomatognathic Diseases
Drug Eruptions
Dermatitis
Erythema Multiforme
Erythema
Drug Hypersensitivity
Hypersensitivity
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Conjunctival Diseases
Eye Diseases
Riboflavin
Vitamin B Complex
Vitamins